Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.39 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.39 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22852326 | 0.98 | PTPN2 (0.44) | PTPN2PTPN1PTPN6CYP17A1NAMPT | |
| SCHEMBL22852277 | 0.77 | NAMPT (0.48) | PTPN2PTPN1PTPN6NAMPTPRKDC | |
| SCHEMBL22852325 | 0.74 | NAMPT (0.48) | PTPN2PTPN1PTPN6NAMPTPRKDC | |
| SCHEMBL20865536 | 0.72 | CYP17A1 (0.68) | PTPN2PTPN1PTPN6CYP17A1NAMPT | |
| SCHEMBL615178 | 0.71 | PSMB8 (0.49) | PTPN2PTPN1PTPN6CYP17A1NAMPT | |
| SCHEMBL13055402 | 0.70 | CYP17A1 (0.59) | CYP17A1NAMPTDRD2PSMB8LIPE | |
| SCHEMBL22895527 | 0.68 | ABL1 (0.65) | CYP17A1NAMPTABL1RIN1 | |
| SCHEMBL23728299 | 0.68 | PSMB8 (0.48) | PTPN2PTPN1PTPN6CYP17A1NAMPT | |
| SCHEMBL29330323 | 0.68 | NPC1 (0.53) | PTPN2PTPN1PTPN6NAMPTDRD2 | |
| SCHEMBL25680801 | 0.68 | MAPT (0.64) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612408-B2 | Pyrazolone-fused pyrimidine compound, preparation method for same and applications thereof | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2026-04-28 | — | — | US | disclosed |
| US-20220259210-A1 | Pyrazolone-Fused Pyrimidine Compound, Preparation Method for Same and Applications Thereof | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2022-08-18 | — | — | US | disclosed |
| EP-3992193-A1 | PYRAZOLOPYRIMIDINE COMPOUND, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2022-05-04 | — | — | EP | disclosed |
| WO-2020259703-A1 | PYRAZOLOPYRIMIDINE COMPOUND, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF | 上海医药集团股份有限公司 | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259210-A1 | Pyrazolone-Fused Pyrimidine Compound, Preparation Method for Same and Applications Thereof | WEE1, WEE2, PDXK | PTPN2 1568/4885PTPN1 1670/4885PTPN6 1638/4885 |
| US-12612408-B2 | Pyrazolone-fused pyrimidine compound, preparation method for same and applications thereof | WEE1, WEE2, TK1 | PTPN2 1024/4885PTPN1 385/4885PTPN6 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.